

Steps taken following Prequalification of Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg Tablets*:

Changes	Product information affected	Accepted on
Product information updated with respect to section 4 of the SmPC and PIL	3,4	November 2018

*Trade names are not prequalified by WHO. This is the national medicines regulatory authority's (NMRA) responsibility. Throughout this WHOPAR the proprietary name is given as an example only.